DxTerity
DxTerity is a healthcare company specializing in RNA-based immune system profiling and precision diagnostic tests for autoimmune diseases, including lupus. The company offers at-home genomic monitoring, COVID-19 testing solutions, and operates a CAP-accredited, CLIA laboratory.
Services
DxTerity offers a range of diagnostic and testing services tailored to autoimmune diseases and immune health monitoring. Their offerings include precision diagnostic tests for diseases like Systemic Lupus Erythematosus (SLE), utilizing the Type-1 Interferon (IFN-1) Test. The company also provides COVID-19 testing solutions, including both individual and corporate tests. Additionally, DxTerity delivers a COVID-19 Employer Screening Service in compliance with OSHA Emergency Temporary Standard (ETS). Their services are complemented by at-home sample collection kits, providing a convenient and patient-centric approach.
Products
DxTerity has developed several key products aimed at improving the diagnosis and monitoring of autoimmune conditions and immune health. These include the Type-1 Interferon (IFN-1) Test for lupus, which measures blood IFN-1 expression. They have also created a patented micro-collection device (MCD) for easy sample collection. Another critical product is the Modular Immune Profile (MIP) test, designed for patient stratification and monitoring therapy responses. Their unique workflow incorporates Non-Enzymatic Chemical Ligation, allowing high-throughput processing without the need for sample purification.
Clinical Studies
DxTerity conducts clinical studies such as ELEVATE, which aims to provide real-world evidence supporting the effectiveness of RNA testing in diagnosing and managing Systemic Lupus Erythematosus (SLE). These studies are essential for validating their precision diagnostic tests and ensuring they deliver the accuracy and reliability needed in clinical settings. Moreover, they connect pharmaceutical, biotechnology, and academic research partners with patient participants in their studies, contributing to broader advancements in the field of autoimmune disease research.
Laboratory Certifications
DxTerity operates a California State licensed, CAP-accredited, CLIA laboratory, ensuring that their diagnostic tests meet stringent quality and accuracy standards. They have also received New York state authorization for their Type-1 Interferon (IFN-1) Gene Signature Testing for SLE patients. These certifications underscore their commitment to delivering high-quality diagnostic solutions that healthcare providers and patients can rely on.
Precision Medicine Approach
DxTerity's precision medicine solutions are designed to give autoimmune patients more personalized and effective care. By utilizing RNA-based immune system profiling and unique testing capabilities like the Type-1 Interferon (IFN-1) Test and the Modular Immune Profile (MIP) test, they enable more accurate diagnosis and monitoring. Their at-home sample collection kits support a patient-centric approach, making it easier for patients to manage their health from the comfort of their home. This approach aims to provide better health outcomes and improve the quality of life for autoimmune patients.